International Journal of Hematology

, Volume 91, Issue 1, pp 136–139

A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders

  • Ping Chong Bee
  • G. G. Gan
  • V. S. Nadarajan
  • N. A. Latiff
  • N. Menaka
Case Report


The co-occurrence of JAK2 V617F mutation with BCR-ABL reciprocal translocation is uncommon. We report a 60-year-old man who initially presented with phenotype of polycythemia vera (PV), which evolved into chronic myeloid leukemia and back to PV once treatment with imatinib was commenced. JAK2 V617F mutation and BCR-ABL fusion transcripts were detected in the initial sample. However, JAK2 V617F alleles diminished when BCR-ABL mRNA burden increased and reappeared once the patient was commenced on imatinib. The dynamic interaction between JAK2 V617F and BCR-ABL implies that two independent clones exist with the JAK2 V617F clone only achieving clonal dominance when BCR-ABL positive clones are suppressed by imatinib.


Chronic myeloid leukemia Polycythemia vera Bcr-Abl JAK2 V617F mutation Stem cell 


  1. 1.
    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.PubMedGoogle Scholar
  2. 2.
    Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.CrossRefPubMedGoogle Scholar
  3. 3.
    Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459–68.CrossRefPubMedGoogle Scholar
  4. 4.
    Bocchia M, Vannucchi AM, Gozzetti A, Guglielmelli P, Poli G, Crupi R, et al. Insights into JAK2-V617F mutation in CML. Lancet Oncol. 2007;8:864–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Bornhauser M, Mohr B, Oelschlaegel U, Bornhauser P, Jacki S, Ehninger G, et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia. 2007;21:1824–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Conchon MR, Costa JL, Novaes MM, Dorlhiac-Llacer PE, de Alencar Fischer Chamone D, Bendit I. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol. 2008;88:243–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Gattenlohner S, Volker HU, Etschmann B, Einsele H, Muller-Hermelink HK. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T). Am J Hematol. 2009;84:306–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood. 2007;109:4106–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia. 2007;21:1103–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Jallades L, Hayette S, Tigaud I, Johnston A, Coiffier B, Magaud JP, et al. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res. 2008;32:1608–10.CrossRefPubMedGoogle Scholar
  11. 11.
    Kramer A, Reiter A, Kruth J, Erben P, Hochhaus A, Muller M, et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol. 2007;8:658–60.CrossRefPubMedGoogle Scholar
  12. 12.
    Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood. 2008;111:2785–9.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  • Ping Chong Bee
    • 1
  • G. G. Gan
    • 1
  • V. S. Nadarajan
    • 2
  • N. A. Latiff
    • 1
  • N. Menaka
    • 2
  1. 1.Department of Medicine, Faculty of MedicineUniversity of MalayaKuala LumpurMalaysia
  2. 2.Department of Pathology, Faculty of MedicineUniversity of MalayaKuala LumpurMalaysia

Personalised recommendations